查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球生物晶片市場按產品/服務、類型、製造技術、最終用戶和地區分類－預測至2030年
市場調查報告書
商品編碼
1881288

全球生物晶片市場按產品/服務、類型、製造技術、最終用戶和地區分類－預測至2030年

Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 412 Pages | 訂單完成後即時交付

價格

預計生物晶片市場將從 2025 年的 140.1 億美元成長到 2030 年的 213.6 億美元，複合年成長率為 8.8%。

這一成長是由塑造診斷技術、基因組學和個人化醫療未來發展的幾個關鍵因素所推動的。

調查範圍
調查期 2023-2030
基準年 2024
預測期 2025-2030
目標單元 金額（十億美元）
部分 按產品/服務、類型、製造技術、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

推動這一成長的主要因素是基因組學進步帶來的精準診斷和個人化治療需求的不斷成長，以及人們對個人化醫療日益濃厚的興趣。隨著醫療產業朝向更個人化的治療方案發展，生物晶片在基因檢測、疾病檢測和藥物研發等領域的應用正在迅速擴展。

生物晶片市場-IMG1

此外，對更快、更有效率診斷的需求日益成長，推動了對高通量就地檢驗方案的需求。生物晶片，特別是DNA晶片和實驗室晶片系統，透過提供快速、經濟高效且擴充性的診斷解決方案，在滿足這一需求方面發揮關鍵作用。醫療保健去中心化的趨勢，即診斷測試和治療從集中式實驗室轉移到更便捷的場所，也進一步推動了生物晶片的應用。

人工智慧的整合和用於數據分析的微流體平台的發展等技術進步也推動了市場成長。這些創新提高了生物晶片系統的準確性、速度和易用性，拓展了其在從科學研究到臨床診斷等各個領域的應用範圍。

總體而言，不斷成長的醫療需求、技術創新以及向個人化和去中心化醫療的持續轉變，共同推動了生物晶片市場的強勁成長。

受生物晶片應用中對高級數據分析、人工智慧驅動的洞察以及雲端整合需求的日益成長的推動，軟體和服務領域預計將成為生物晶片市場成長最快的板塊。生物晶片會產生大量複雜的生物數據，需要先進的軟體解決方案來處理、解讀和視覺化這些數據。此外，個人化醫療和精準診斷的興起也推動了對生物資訊服務的需求，以處理和分析遺傳、蛋白質組和基因組數據。這些趨勢，加上雲端基礎平台在數據共用和遠距離診斷的日益普及，共同推動了生物晶片市場軟體和服務領域的快速成長。

2024年，獸醫院領域引領了生物晶片市場，這主要歸功於生物晶片在藥物研發、基因組研究和個人化醫療中發揮的關鍵作用。這些公司利用生物晶片進行高通量篩檢、生物標記發現和基因分析，這些對於開發新治療方法和提高治療精準度至關重要。對更快、更準確、更經濟高效的診斷和研發工具日益成長的需求，推動了這些產業對生物晶片的強勁需求。此外，生物晶片還能幫助製藥公司簡化藥物研發流程，使其成為生技和製藥領域不可或缺的技術。

亞太地區預計將成為生物晶片市場成長最快的地區，這主要得益於醫療基礎設施的快速發展、政府對生物技術領域投資的不斷增加以及對個人化醫療日益成長的關注。該地區蓬勃發展的製藥和生物技術產業正在推動藥物研發、診斷和基因組研究領域對生物晶片的需求。此外，中國和印度等國家不斷提高的健康意識、醫療服務可近性的改善以及中產階級的壯大，正在加速包括生物晶片在內的先進診斷技術的應用。經濟成長、技術進步和醫療創新三者共同推動著該地區市場的快速擴張。

本報告對全球生物晶片市場進行了研究，並按產品/服務、類型、製造技術、最終用戶、區域趨勢和公司概況對市場進行了全面分析。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章重要考察

第5章 市場概覽

  • 介紹
  • 市場動態
  • 產業趨勢
  • 技術分析
  • 波特五力分析
  • 監管狀態
  • 專利分析
  • 貿易分析
  • 定價分析
  • 2025-2026 年主要會議和活動
  • 主要相關人員和採購標準
  • 最終用戶分析和未滿足的需求
  • 人工智慧/生成式人工智慧對生物晶片市場的影響
  • 生態系分析
  • 案例研究分析
  • 價值鏈分析
  • 供應鏈分析
  • 影響客戶業務的趨勢/顛覆性因素
  • 投資和資金籌措方案
  • 美國關稅對生物晶片市場的影響

第6章 生物晶片市場（依產品和服務分類）

  • 介紹
  • 消耗品
  • 裝置
  • 軟體和服務

第7章 生物晶片市場（依類型）

  • 介紹
  • DNA晶片
  • 實驗室晶片
  • 蛋白質晶片
  • 組織陣列
  • 細胞陣列

第8章 生物晶片市場（依製造技術分類）

  • 介紹
  • 微陣列
  • 微流體

第9章 生物晶片市場（依最終用戶分類）

  • 介紹
  • 生物技術和製藥公司
  • 醫院和診斷中心
  • 學術研究機構
  • CRO
  • 其他

第10章 生物晶片市場（依地區分類）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 北美：按類型分類的銷售分析，2023-2030 年（千單位）
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 歐洲：按類型分類的銷售分析，2023-2030 年（千台）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 亞太地區：按類型分類的銷售分析，2023-2030 年（千台）
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 紐西蘭
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 拉丁美洲：按類型分類的銷售分析，2023-2030 年（1000 單位）
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 中東和非洲宏觀經濟展望
    • 中東和非洲：按類型分類的銷售分析，2023-2030 年（1000 單位）
    • 海灣合作理事會國家
    • 其他

第11章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2020-2024年收入佔有率分析
  • 2024年市佔率分析
  • 估值和財務指標
  • 品牌/產品比較分析
  • 主要企業的研發支出
  • 公司估值矩陣：主要參與企業，2024 年
  • 公司估值矩陣：Start-Ups/中小企業，2024 年
  • 競爭場景

第12章：公司簡介

  • 主要參與企業
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • AGILENT TECHNOLOGIES, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • QIAGEN
    • BIO-RAD LABORATORIES, INC.
    • ABBOTT
    • STANDARD BIOTOOLS
    • 10X GENOMICS
    • CEPHEID
    • BIOMERIEUX
    • REVVITY
    • DIASORIN SPA
    • RANDOX LABORATORIES LTD.
    • OXFORD GENE TECHNOLOGY IP LIMITED
  • 其他公司
    • MICRONIT BV
    • RAYBIOTECH, INC.
    • PHALANX BIOTECH GROUP
    • ARRAYIT CORPORATION
    • 3DHISTECH LTD.
    • CREATIVE BIOARRAY
    • TISSUEARRAY.COM
    • IBIOCHIPS
    • CAPITALBIOTECH CO., LTD.
    • PEPPERPRINT GMBH

第13章附錄

Product Code: MD 4275

The biochips market is expected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8%. This growth is driven by several key factors shaping the future of diagnostics, genomics, and personalized medicine.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsBy Product & Service, By Type, By Fabrication Technology, By End User, By Region
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

A major driver of this growth is the increasing demand for precision diagnostics and personalized treatments, fueled by advancements in genomics and the growing focus on individualized healthcare. As the healthcare industry shifts toward more tailored treatment plans, the adoption of biochips for applications like genetic testing, disease detection, and drug development is rapidly expanding.

Biochips Market - IMG1

Additionally, the growing demand for faster and more efficient diagnostics is driving the need for high-throughput, point-of-care testing solutions. Biochips, particularly DNA chips and lab-on-a-chip systems, play a crucial role in meeting this demand by providing rapid, cost-effective, and scalable diagnostic solutions. The ongoing trend toward decentralization in healthcare, where diagnostic tests and treatments are moving from centralized laboratories to more accessible settings, further boosts the adoption of biochips.

Technological advancements, such as the integration of artificial intelligence for data analysis and the development of microfluidic platforms, are also accelerating market growth. These innovations enhance the accuracy, speed, and ease of use of biochip systems, expanding their applications across various sectors, from research to clinical diagnostics.

Overall, the combination of rising healthcare demands, technological innovations, and the increasing shift toward personalized and decentralized healthcare is driving robust growth in the biochips market.

By product & service, the software & services segment is projected to grow at the highest CAGR during the forecast period.

The software & services segment is expected to see the highest growth in the biochips market, driven by the increasing need for advanced data analysis, AI-driven insights, and cloud integration in biochip applications. As biochips generate large volumes of complex biological data, sophisticated software solutions are essential for processing, interpreting, and visualizing results. Additionally, the rise in personalized medicine and precision diagnostics requires bioinformatics services to handle and analyze genetic, proteomic, and genomic data. These trends, coupled with the growing adoption of cloud-based platforms for data sharing and remote diagnostics, are driving the rapid growth of software and services in the biochips market.

By end user, the biotechnology and pharmaceutical companies segment accounted for the largest market share in 2024.

In 2024, the veterinary clinics segment dominated the biochips market due to the critical role biochips play in drug discovery, genomic research, and personalized medicine. These companies use biochips for high-throughput screening, biomarker discovery, and genetic profiling, which are essential for developing new therapies and improving treatment precision. The need for faster, more accurate, and cost-effective diagnostics and research tools drives strong demand for biochips in these industries. Additionally, biochips enable pharmaceutical companies to streamline drug development processes, making them an indispensable technology in the biotech and pharmaceutical sectors.

The Asia Pacific region is expected to witness the highest growth during the forecast period.

The Asia Pacific is poised to experience the highest growth in the biochips market, driven by rapid advancements in healthcare infrastructure, increasing government investments in biotechnology, and a growing focus on personalized medicine. The region's expanding pharmaceutical and biotechnology industries are driving demand for biochips in drug development, diagnostics, and genomic research. Additionally, rising healthcare awareness, improved healthcare access, and a growing middle class in countries such as China and India are accelerating the adoption of advanced diagnostic technologies, including biochips. This combination of economic growth, technological advancements, and healthcare innovations is driving the region's rapid market expansion.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
  • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

  • By End User: Biotechnology and Pharmaceutical Companies (40%), Hospitals and Diagnostic Centers (25%), Academic & Research Institutes (20%), Contract Research Organizations (CROs) (10%), and Other End Users (5%)

By Designation: Laboratory Managers / Heads (47%), Clinical Diagnostics Managers (22%), Genomics / Research Scientists (15%), and Others (16%)

  • By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the biochips market in various segments. It aims to estimate the market size and growth potential of this market by products & services, type, fabrication technology, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

  • Analysis of key drivers (Growing demand for personalized medicines, Technological advancements in microfluidics and AI integration), restraints (High cost of biochip development and fabrication, Data management and standardization issues), opportunities (Expanding applications in point-of-care and decentralized diagnostics, Increasing government and private investments in genomics research), and challenges (Technical complexity and integration of multidisciplinary technologies, Regulatory and validation hurdles for clinical use) influencing the growth of the biochips market.
  • Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the biochips market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biochips across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the biochips market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the biochips market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 MARKET SHARE ANALYSIS
    • 2.5.1 RESEARCH ASSUMPTIONS
    • 2.5.2 GROWTH RATE ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BIOCHIPS MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCTS & SERVICES & COUNTRY (2024)
  • 4.3 BIOCHIPS MARKET: REGIONAL MIX
  • 4.4 BIOCHIPS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.5 BIOCHIPS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising adoption of personalized medicine
      • 5.2.1.2 Technological advancements in microarray and microfluidics fabrication
      • 5.2.1.3 Increasing R&D investments in genomics and proteomics
      • 5.2.1.4 Advancements in point-of-care diagnostics and lab-on-a-chip technologies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of instruments and fabrication
      • 5.2.2.2 Complex data interpretation and standardization
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Integration of AI and bioinformatics in biochip data analysis
      • 5.2.3.2 Expansion into emerging markets and new applications
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical complexity and integration of multidisciplinary technologies
      • 5.2.4.2 Regulatory and validation hurdles for clinical use
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 MINIATURIZATION, PORTABILITY, AND DECENTRALIZED DIAGNOSTICS
    • 5.3.2 SHIFT TOWARD MICROFLUIDICS AND LAB-ON-A-CHIP FORMATS
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Digital microfluidic biochips
      • 5.4.1.2 Plasmonic and nanoplasmonic biochips
      • 5.4.1.3 Wearable and implantable biochips
    • 5.4.2 ADJACENT TECHNOLOGIES
      • 5.4.2.1 AI/Machine learning for biochip data & design
      • 5.4.2.2 Optical genome mapping chips
    • 5.4.3 COMPLEMENTARY TECHNOLOGIES
      • 5.4.3.1 Advanced microfabrication and 3D printing
      • 5.4.3.2 Biochip integration in biosensors
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY ANALYSIS
    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 PATENT ANALYSIS
    • 5.7.1 PATENT PUBLICATION TRENDS FOR BIOCHIPS
    • 5.7.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.8 TRADE ANALYSIS
    • 5.8.1 IMPORT DATA FOR HS CODE 9027
    • 5.8.2 EXPORT DATA FOR HS CODE 9027
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
      • 5.9.2.1 Average selling price of DNA chips and lab-on-a-chip, by region
      • 5.9.2.2 Average selling price trend of DNA chips, by region
      • 5.9.2.3 Average selling price trend of lab-on-a-chip, by region
      • 5.9.2.4 Average selling price trend of protein chips, by region
  • 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.11.2 BUYING CRITERIA
  • 5.12 END-USER ANALYSIS AND UNMET NEEDS
  • 5.13 IMPACT OF AI/GENERATIVE AI ON BIOCHIPS MARKET
    • 5.13.1 INTRODUCTION
    • 5.13.2 MARKET POTENTIAL IN BIOCHIPS ECOSYSTEM
    • 5.13.3 AI-USE CASES
    • 5.13.4 KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET
  • 5.14 ECOSYSTEM ANALYSIS
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 MICROFLUIDIC BIOCHIP-BASED MULTIPLEXED PROFILING FOR EARLY CANCER DETECTION
    • 5.15.2 POINT-OF-CARE TUMOR MARKER DETECTION BIOCHIP
    • 5.15.3 GRAPHENE QUANTUM DOT-BASED BIOCHIP FOR CHILDHOOD LEUKEMIA DETECTION
  • 5.16 VALUE CHAIN ANALYSIS
  • 5.17 SUPPLY CHAIN ANALYSIS
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.19 INVESTMENT AND FUNDING SCENARIO
  • 5.20 US TARIFF IMPACT ON BIOCHIPS MARKET
    • 5.20.1 INTRODUCTION
    • 5.20.2 KEY TARIFF RATES
    • 5.20.3 PRICE IMPACT ANALYSIS
    • 5.20.4 IMPACT ON COUNTRY/REGION
    • 5.20.5 IMPACT ON END-USE INDUSTRIES
      • 5.20.5.1 Biotechnology and pharmaceutical companies
      • 5.20.5.2 Hospitals and diagnostic centers
      • 5.20.5.3 Academic & research institutes
      • 5.20.5.4 Contract Research Organizations (CROs)
      • 5.20.5.5 Other end users

6 BIOCHIPS MARKET, BY PRODUCTS & SERVICES

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 SURGE IN APPLICATIONS ACROSS PERSONALIZED MEDICINE AND PRECISION DIAGNOSTICS TO AID GROWTH
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING DEMAND FOR ADVANCED INSTRUMENTS TO ENHANCE PRECISION AND EFFICIENCY TO DRIVE MARKET
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 INCREASING NEED FOR ADVANCED DATA ANALYSIS AND BIOINFORMATICS TO SUPPORT GROWTH

7 BIOCHIPS MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 DNA CHIPS
    • 7.2.1 GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023-2030 (THOUSAND UNITS)
    • 7.2.2 DNA CHIPS MARKET, BY APPLICATION
      • 7.2.2.1 Gene expression
        • 7.2.2.1.1 Increasing cancer incidence and rising funding for genomic research to foster growth
      • 7.2.2.2 SNP genotyping
        • 7.2.2.2.1 Growing adoption of genetic screening programs and direct-to-consumer genomics services to fuel market
      • 7.2.2.3 Cancer diagnostics & treatment
        • 7.2.2.3.1 Rising global cancer burden and expanding reimbursement coverage to spur growth
      • 7.2.2.4 Genomics
        • 7.2.2.4.1 Rise of personalized medicine and increasing need for non-invasive diagnostics to facilitate growth
      • 7.2.2.5 Drug discovery
        • 7.2.2.5.1 Increasing application of DNA chips in drug discovery to identify targets and optimize therapeutics to boost market
      • 7.2.2.6 Agricultural biotechnology
        • 7.2.2.6.1 Growing use of DNA chips for crop improvement and trait analysis to propel market
      • 7.2.2.7 Other DNA chip applications
  • 7.3 LAB-ON-A-CHIP
    • 7.3.1 GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023-2030 (THOUSAND UNITS)
    • 7.3.2 LAB-ON-A-CHIP MARKET, BY APPLICATION
      • 7.3.2.1 Clinical diagnostics
        • 7.3.2.1.1 Rising burden of chronic and infectious diseases to accelerate growth
      • 7.3.2.2 Genomics
        • 7.3.2.2.1 Increasing proliferation of genomic testing programs to stimulate growth
      • 7.3.2.3 IVD & POC
        • 7.3.2.3.1 Growing emphasis on early disease detection, chronic disease monitoring, and home-based testing to fuel market
      • 7.3.2.4 Proteomics
        • 7.3.2.4.1 Rise in biologic and biosimilar development to contribute to growth
      • 7.3.2.5 Drug discovery
        • 7.3.2.5.1 Increasing demand for high-throughput screening to augment growth
      • 7.3.2.6 Other LOAC applications
  • 7.4 PROTEIN CHIPS
    • 7.4.1 GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023-2030 (THOUSAND UNITS)
    • 7.4.2 PROTEIN CHIPS MARKET, BY APPLICATION
      • 7.4.2.1 Proteomics
        • 7.4.2.1.1 Increasing focus on large-scale protein profiling to aid growth
      • 7.4.2.2 Expression profiling
        • 7.4.2.2.1 Surge in demand for systems-level understanding of cellular processes to support growth
      • 7.4.2.3 Diagnostics
        • 7.4.2.3.1 Increasing integration of protein-chip technology into clinical diagnostic workflows to encourage growth
      • 7.4.2.4 High-throughput screening
        • 7.4.2.4.1 Rising demand for rapid target validation and growing complexity of biologic therapeutics to drive market
      • 7.4.2.5 Drug discovery
        • 7.4.2.5.1 Need for efficient target identification and screening to favor growth
      • 7.4.2.6 Other protein chip applications
  • 7.5 TISSUE ARRAYS
    • 7.5.1 INCREASING DEMAND FOR LARGE-SCALE VALIDATION OF BIOMARKERS TO SPUR GROWTH
    • 7.5.2 GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023-2030 (THOUSAND UNITS)
  • 7.6 CELL ARRAYS
    • 7.6.1 EXPANDING USE OF CELL ARRAYS FOR HIGH-THROUGHPUT CELLULAR ANALYSIS AND DRUG SCREENING TO AID GROWTH
    • 7.6.2 GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023-2030 (THOUSAND UNITS)

8 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 MICROARRAYS
    • 8.2.1 WIDESPREAD ADOPTION OF MICROARRAYS IN GENOMIC AND PROTEOMIC RESEARCH TO FUEL MARKET
  • 8.3 MICROFLUIDICS
    • 8.3.1 GROWING DEMAND FOR DECENTRALIZED, POINT-OF-CARE DIAGNOSTICS, AND HIGH-THROUGHPUT SCREENING TOOLS TO DRIVE MARKET

9 BIOCHIPS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
    • 9.2.1 RISING TREND OF PERSONALIZED AND PRECISION THERAPEUTICS TO EXPEDITE GROWTH
  • 9.3 HOSPITALS & DIAGNOSTIC CENTERS
    • 9.3.1 INCREASING HOSPITAL INVESTMENTS IN MOLECULAR PATHOLOGY TO EXPEDITE GROWTH
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 GROWING USE OF BIOCHIPS IN GENE-FUNCTION RELATIONSHIPS, PROTEIN NETWORKS, AND DISEASE MECHANISMS TO BOOST MARKET
  • 9.5 CONTRACT RESEARCH ORGANIZATIONS (CROS)
    • 9.5.1 INCREASING TREND OF OUTSOURCING RESEARCH AND DEVELOPMENT ACTIVITIES TO PROMOTE GROWTH
  • 9.6 OTHER END USERS

10 BIOCHIPS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
    • 10.2.3 US
      • 10.2.3.1 Presence of prominent companies and high cancer prevalence to expedite growth
    • 10.2.4 CANADA
      • 10.2.4.1 Expanding genomics and precision medicine initiatives to drive market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 EUROPE: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
    • 10.3.3 GERMANY
      • 10.3.3.1 Robust ecosystem of biotech startups and multinational corporations to promote growth
    • 10.3.4 UK
      • 10.3.4.1 Increasing healthcare investments and genomic advancements to drive market
    • 10.3.5 FRANCE
      • 10.3.5.1 Strong government initiatives in biotechnology, precision medicine, and healthcare innovations to boost market
    • 10.3.6 ITALY
      • 10.3.6.1 Growing demand for precision medicine to spur growth
    • 10.3.7 SPAIN
      • 10.3.7.1 Increasing demand for personalized medicine and strong governmental & institutional support to propel market
    • 10.3.8 NETHERLANDS
      • 10.3.8.1 Increasing emphasis on genomics and personalized medicine to favor growth
    • 10.3.9 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
    • 10.4.3 CHINA
      • 10.4.3.1 Rising healthcare demand to support growth
    • 10.4.4 JAPAN
      • 10.4.4.1 Increasing geriatric population to drive market
    • 10.4.5 INDIA
      • 10.4.5.1 Strong government support for domestic biotech manufacturing to facilitate growth
    • 10.4.6 AUSTRALIA
      • 10.4.6.1 Increasing advancements in biotechnology to spur growth
    • 10.4.7 SOUTH KOREA
      • 10.4.7.1 Increasing healthcare expenditure to expedite growth
    • 10.4.8 THAILAND
      • 10.4.8.1 Rising healthcare investments to accelerate growth
    • 10.4.9 NEW ZEALAND
      • 10.4.9.1 Increasing focus on early detection and improving survival rates to drive market
    • 10.4.10 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
    • 10.5.3 BRAZIL
      • 10.5.3.1 Increasing demand for precision medicine and advancements in genomics to foster growth
    • 10.5.4 MEXICO
      • 10.5.4.1 Rising prevalence of chronic and infectious conditions to contribute to growth
    • 10.5.5 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
    • 10.6.3 GCC COUNTRIES
      • 10.6.3.1 Kingdom of Saudi Arabia (KSA)
        • 10.6.3.1.1 Strong public healthcare funding and rapid expansion of hospital infrastructure to aid growth
      • 10.6.3.2 United Arab Emirates (UAE)
        • 10.6.3.2.1 Growing integration of advanced diagnostic technologies to fuel market
      • 10.6.3.3 Rest of GCC Countries
    • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.3 REVENUE SHARE ANALYSIS, 2020-2024
  • 11.4 MARKET SHARE ANALYSIS, 2024
    • 11.4.1 GLOBAL MARKET SHARE ANALYSIS, 2024
    • 11.4.2 US MARKET SHARE ANALYSIS, 2024
  • 11.5 COMPANY VALUATION AND FINANCIAL METRICS
    • 11.5.1 COMPANY VALUATION
    • 11.5.2 FINANCIAL METRICS
  • 11.6 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 11.7 R&D EXPENDITURE OF KEY PLAYERS
  • 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.8.1 STARS
    • 11.8.2 EMERGING LEADERS
    • 11.8.3 PERVASIVE PLAYERS
    • 11.8.4 PARTICIPANTS
    • 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.8.5.1 Company footprint
      • 11.8.5.2 Region footprint
      • 11.8.5.3 Product & service footprint
      • 11.8.5.4 Type footprint
      • 11.8.5.5 Fabrication technology footprint
  • 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.9.1 PROGRESSIVE COMPANIES
    • 11.9.2 RESPONSIVE COMPANIES
    • 11.9.3 DYNAMIC COMPANIES
    • 11.9.4 STARTING BLOCKS
    • 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 11.9.5.1 Detailed list of key startups/SMEs
      • 11.9.5.2 Competitive benchmarking of key startups/SMEs
  • 11.10 COMPETITIVE SCENARIO
    • 11.10.1 PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 11.10.2 DEALS
    • 11.10.3 EXPANSIONS
    • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 THERMO FISHER SCIENTIFIC INC.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products/Services offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 ILLUMINA, INC.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products/Services offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 AGILENT TECHNOLOGIES, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products/Services offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
        • 12.1.3.3.2 Expansions
        • 12.1.3.3.3 Other developments
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 F. HOFFMANN-LA ROCHE LTD
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products/Services offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 QIAGEN
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products/Services offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.5.3.2 Deals
        • 12.1.5.3.3 Expansions
        • 12.1.5.3.4 Other developments
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 BIO-RAD LABORATORIES, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products/Services offered
    • 12.1.7 ABBOTT
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products/Services offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Product/Service launches, enhancements, and approvals
    • 12.1.8 STANDARD BIOTOOLS
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products/Services offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.8.3.2 Deals
        • 12.1.8.3.3 Other developments
    • 12.1.9 10X GENOMICS
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products/Services offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.9.3.2 Deals
        • 12.1.9.3.3 Other developments
    • 12.1.10 CEPHEID
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products/Services offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.10.3.2 Deals
        • 12.1.10.3.3 Other developments
    • 12.1.11 BIOMERIEUX
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products/Services offered
        • 12.1.11.2.1 Product/Service launches, enhancements, and approvals
        • 12.1.11.2.2 Deals
    • 12.1.12 REVVITY
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products/Services offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Deals
    • 12.1.13 DIASORIN S.P.A.
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products/Services offered
    • 12.1.14 RANDOX LABORATORIES LTD.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products/Services offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Product/Service launches, enhancements, and approvals
        • 12.1.14.3.2 Deals
        • 12.1.14.3.3 Expansions
    • 12.1.15 OXFORD GENE TECHNOLOGY IP LIMITED
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products/Services offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 MICRONIT B.V.
    • 12.2.2 RAYBIOTECH, INC.
    • 12.2.3 PHALANX BIOTECH GROUP
    • 12.2.4 ARRAYIT CORPORATION
    • 12.2.5 3DHISTECH LTD.
    • 12.2.6 CREATIVE BIOARRAY
    • 12.2.7 TISSUEARRAY.COM
    • 12.2.8 IBIOCHIPS
    • 12.2.9 CAPITALBIOTECH CO., LTD.
    • 12.2.10 PEPPERPRINT GMBH

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
    • 13.3.1 PRODUCT ANALYSIS
    • 13.3.2 COMPANY INFORMATION
    • 13.3.3 GEOGRAPHIC ANALYSIS
    • 13.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
    • 13.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
    • 13.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
    • 13.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 BIOCHIPS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES, 2021-2024 (UNIT OF USD)
  • TABLE 3 BIOCHIPS MARKET: RISK ASSESSMENT
  • TABLE 4 BIOCHIPS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 BIOCHIPS MARKET: MAJOR PATENTS, 2022-2025
  • TABLE 9 IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020-2024 (USD THOUSANDS)
  • TABLE 10 EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020-2024 (USD THOUSANDS)
  • TABLE 11 AVERAGE SELLING PRICE TREND OF BIOCHIPS, BY KEY PLAYER, 2022-2024
  • TABLE 12 AVERAGE SELLING PRICE TREND OF DNA CHIPS, BY REGION, 2022-2024
  • TABLE 13 AVERAGE SELLING PRICE TREND FOR LAB-ON-A-CHIP, BY REGION, 2022-2024
  • TABLE 14 AVERAGE SELLING PRICE TREND OF PROTEIN CHIPS, BY REGION, 2022-2024
  • TABLE 15 BIOCHIPS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS, BY PRODUCT
  • TABLE 17 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 18 KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET
  • TABLE 19 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 KEY PRODUCT-RELATED TARIFF EFFECTIVE BIOCHIPS
  • TABLE 21 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
  • TABLE 22 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
  • TABLE 23 EUROPE: IMPACT ON GERMANY AND UK DUE TO THE US TARIFFS
  • TABLE 24 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
  • TABLE 25 BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2023-2030 (USD MILLION)
  • TABLE 26 BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 KEY PLAYERS PROVIDING BIOCHIP CONSUMABLES
  • TABLE 28 BIOCHIPS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 KEY PLAYERS PROVIDING BIOCHIP INSTRUMENTS
  • TABLE 30 BIOCHIPS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 KEY PLAYERS PROVIDING BIOCHIPS SOFTWARE & SERVICES
  • TABLE 32 BIOCHIPS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 34 DNA CHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023-2030 (THOUSAND UNITS)
  • TABLE 36 DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 37 KEY PLAYERS PROVIDING DNA CHIPS FOR GENE EXPRESSION
  • TABLE 38 DNA CHIPS MARKET FOR GENE EXPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 KEY PLAYERS PROVIDING DNA CHIPS FOR SNP GENOTYPING
  • TABLE 40 DNA CHIPS MARKET FOR SNP GENOTYPING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 KEY PLAYERS PROVIDING DNA CHIPS FOR CANCER DIAGNOSTICS & TREATMENT
  • TABLE 42 DNA CHIPS MARKET FOR CANCER DIAGNOSTICS & TREATMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 KEY PLAYERS PROVIDING DNA CHIPS FOR GENOMICS
  • TABLE 44 DNA CHIPS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 DNA CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 DNA CHIPS MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 DNA CHIPS MARKET FOR OTHER DNA CHIP APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 LAB-ON-A-CHIP MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023-2030 (THOUSAND UNITS)
  • TABLE 50 LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 51 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR CLINICAL DIAGNOSTIC
  • TABLE 52 LAB-ON-A-CHIP MARKET FOR CLINICAL DIAGNOSTIC, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR GENOMICS
  • TABLE 54 LAB-ON-A-CHIP MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR IVD & POC
  • TABLE 56 LAB-ON-A-CHIP MARKET FOR IVD & POC, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR PROTEOMICS
  • TABLE 58 LAB-ON-A-CHIP MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 LAB-ON-A-CHIP MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 LAB-ON-A-CHIP MARKET FOR OTHER LOAC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 PROTEIN CHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023-2030 (THOUSAND UNITS)
  • TABLE 63 PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 64 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR PROTEOMICS
  • TABLE 65 PROTEIN CHIPS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR EXPRESSION PROFILING
  • TABLE 67 PROTEIN CHIPS MARKET FOR EXPRESSION PROFILING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR DIAGNOSTICS
  • TABLE 69 PROTEIN CHIPS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR HIGH-THROUGHPUT SCREENING
  • TABLE 71 PROTEIN CHIPS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 PROTEIN CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 PROTEIN CHIPS MARKET FOR OTHER PROTEIN CHIP APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 KEY PLAYERS PROVIDING TISSUE ARRAYS
  • TABLE 75 TISSUE ARRAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023-2030 (THOUSAND UNITS)
  • TABLE 77 KEY PLAYERS PROVIDING CELL ARRAYS
  • TABLE 78 BIOCHIPS MARKET FOR CELL ARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023-2030 (THOUSAND UNITS)
  • TABLE 80 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 81 KEY PLAYERS PROVIDING BIOCHIP MICROARRAYS
  • TABLE 82 BIOCHIPS MARKET FOR MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 KEY PLAYERS PROVIDING MICROFLUIDICS
  • TABLE 84 BIOCHIPS MARKET FOR MICROFLUIDICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 86 BIOCHIPS MARKET FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 BIOCHIPS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 BIOCHIPS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 BIOCHIPS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 BIOCHIPS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 BIOCHIPS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 93 NORTH AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 101 US: KEY MACROECONOMIC INDICATORS
  • TABLE 102 US: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 103 US: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 104 US: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 105 US: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 106 US: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 107 US: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 108 US: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 109 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 110 CANADA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 111 CANADA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 112 CANADA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 113 CANADA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 114 CANADA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 115 CANADA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 116 CANADA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 117 EUROPE: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 118 EUROPE: BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 120 EUROPE: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 121 EUROPE: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 123 EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 124 EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 125 EUROPE: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 126 GERMANY: KEY MACROECONOMIC INDICATORS
  • TABLE 127 GERMANY: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 128 GERMANY: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 129 GERMANY: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 130 GERMANY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 131 GERMANY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 132 GERMANY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 133 GERMANY: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 134 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 135 UK: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 136 UK: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 137 UK: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 138 UK: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 139 UK: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 140 UK: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 141 UK: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 142 FRANCE: KEY MACROECONOMIC INDICATORS
  • TABLE 143 FRANCE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 144 FRANCE: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 145 FRANCE: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 146 FRANCE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 147 FRANCE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 148 FRANCE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 149 FRANCE: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 150 ITALY: KEY MACROECONOMIC INDICATORS
  • TABLE 151 ITALY: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 152 ITALY: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 153 ITALY: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 154 ITALY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 155 ITALY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 156 ITALY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 157 ITALY: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 158 SPAIN: KEY MACROECONOMIC INDICATORS
  • TABLE 159 SPAIN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 160 SPAIN: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 161 SPAIN: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 162 SPAIN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 163 SPAIN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 164 SPAIN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 165 SPAIN: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 166 NETHERLANDS: KEY MACROECONOMIC INDICATORS
  • TABLE 167 NETHERLANDS: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 168 NETHERLANDS: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 169 NETHERLANDS: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 170 NETHERLANDS: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 171 NETHERLANDS: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 172 NETHERLANDS: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 173 NETHERLANDS: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 174 REST OF EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 175 REST OF EUROPE: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 REST OF EUROPE: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 177 REST OF EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 179 REST OF EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF EUROPE: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 182 ASIA PACIFIC: BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 190 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 191 CHINA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 192 CHINA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 CHINA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 194 CHINA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 195 CHINA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 196 CHINA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 197 CHINA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 198 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 199 JAPAN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 200 JAPAN: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 201 JAPAN: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 202 JAPAN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 203 JAPAN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 204 JAPAN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 205 JAPAN: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 206 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 207 INDIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 208 INDIA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 INDIA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 210 INDIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 211 INDIA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 212 INDIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 213 INDIA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 214 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 215 AUSTRALIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 216 AUSTRALIA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 217 AUSTRALIA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 218 AUSTRALIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 219 AUSTRALIA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 220 AUSTRALIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 221 AUSTRALIA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 222 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
  • TABLE 223 SOUTH KOREA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 224 SOUTH KOREA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 225 SOUTH KOREA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 226 SOUTH KOREA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 227 SOUTH KOREA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 228 SOUTH KOREA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 229 SOUTH KOREA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 230 THAILAND: KEY MACROECONOMIC INDICATORS
  • TABLE 231 THAILAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 232 THAILAND: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 233 THAILAND: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 234 THAILAND: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 235 THAILAND: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 236 THAILAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 237 THAILAND: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 238 NEW ZEALAND: KEY MACROECONOMIC INDICATORS
  • TABLE 239 NEW ZEALAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 240 NEW ZEALAND: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 241 NEW ZEALAND: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 242 NEW ZEALAND: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 243 NEW ZEALAND: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 244 NEW ZEALAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 245 NEW ZEALAND: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 246 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 247 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 REST OF ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 249 REST OF ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 250 REST OF ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 251 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 252 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 253 LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 254 LATIN AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 255 LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 256 LATIN AMERICA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 257 LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 258 LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 259 LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 260 LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 261 LATIN AMERICA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 262 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 263 BRAZIL: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 264 BRAZIL: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 265 BRAZIL: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 266 BRAZIL: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 267 BRAZIL: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 268 BRAZIL: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 269 BRAZIL: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 270 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 271 MEXICO: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 272 MEXICO: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 273 MEXICO: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 274 MEXICO: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 275 MEXICO: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 276 MEXICO: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 277 MEXICO: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 278 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 279 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 280 REST OF LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 281 REST OF LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 282 REST OF LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 283 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 284 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 285 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 286 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 287 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 288 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 289 MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 290 MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 291 MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 292 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 293 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 294 GCC COUNTRIES: BIOCHIPS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 295 GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 296 GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 298 GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 299 GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 300 GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 301 GCC COUNTRIES: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 302 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS
  • TABLE 303 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 304 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 305 KINGDOM OF SAUDI ARABIA (KSA): DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 306 KINGDOM OF SAUDI ARABIA (KSA): LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 307 KINGDOM OF SAUDI ARABIA (KSA): PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 308 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 309 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 310 UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS
  • TABLE 311 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 312 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 313 UNITED ARAB EMIRATES (UAE): DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 314 UNITED ARAB EMIRATES (UAE): LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 315 UNITED ARAB EMIRATES (UAE): PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 316 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 317 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 318 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 319 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 REST OF GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 321 REST OF GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 322 REST OF GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 323 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 324 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 325 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 326 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 327 REST OF MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 328 REST OF MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 329 REST OF MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 330 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 331 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 332 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOCHIPS MARKET, 2022-2024
  • TABLE 333 GLOBAL BIOCHIPS MARKET: DEGREE OF COMPETITION
  • TABLE 334 US BIOCHIPS MARKET: DEGREE OF COMPETITION
  • TABLE 335 BIOCHIPS MARKET: REGION FOOTPRINT
  • TABLE 336 BIOCHIPS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 337 BIOCHIPS MARKET: TYPE FOOTPRINT
  • TABLE 338 BIOCHIPS MARKET: FABRICATION TECHNOLOGY FOOTPRINT
  • TABLE 339 BIOCHIPS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 340 BIOCHIPS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 341 BIOCHIPS MARKET: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 342 BIOCHIPS MARKET: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 343 BIOCHIPS MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 344 BIOCHIPS MARKET: OTHERS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 345 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 346 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 347 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 348 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 349 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 350 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 351 ILLUMINA, INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 352 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 353 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 354 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 355 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 356 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 357 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 358 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 359 F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 360 QIAGEN: COMPANY OVERVIEW
  • TABLE 361 QIAGEN: PRODUCTS/SERVICES OFFERED
  • TABLE 362 QIAGEN: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 363 QIAGEN: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 364 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 365 QIAGEN: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 366 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 367 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 368 ABBOTT: COMPANY OVERVIEW
  • TABLE 369 ABBOTT: PRODUCTS/SERVICES OFFERED
  • TABLE 370 ABBOTT: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 371 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • TABLE 372 STANDARD BIOTOOLS: PRODUCTS/SERVICES OFFERED
  • TABLE 373 STANDARD BIOTOOLS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 374 STANDARD BIOTOOLS INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 375 STANDARD BIOTOOLS INC.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 376 10X GENOMICS: COMPANY OVERVIEW
  • TABLE 377 10X GENOMICS: PRODUCTS/SERVICES OFFERED
  • TABLE 378 10X GENOMICS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 379 10X GENOMICS: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 380 10X GENOMICS: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 381 CEPHEID: COMPANY OVERVIEW
  • TABLE 382 CEPHEID: PRODUCTS/SERVICES OFFERED
  • TABLE 383 CEPHEID: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 384 CEPHEID: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 385 CEPHEID: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 386 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 387 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
  • TABLE 388 BIOMERIEUX: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 389 BIOMERIEUX: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 390 REVVITY: COMPANY OVERVIEW
  • TABLE 391 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 392 REVVITY: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 393 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 394 DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 395 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 396 RANDOX LABORATORIES LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 397 RANDOX LABORATORIES LTD.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 398 RANDOX LABORATORIES LTD.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 399 RANDOX LABORATORIES LTD.: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 400 OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW
  • TABLE 401 OXFORD GENE TECHNOLOGY IP LIMITED: PRODUCTS/SERVICES OFFERED
  • TABLE 402 MICRONIT B.V.: COMPANY OVERVIEW
  • TABLE 403 RAYBIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 404 PHALANX BIOTECH GROUP: COMPANY OVERVIEW
  • TABLE 405 ARRAYIT CORPORATION: COMPANY OVERVIEW
  • TABLE 406 3DHISTECH LTD.: COMPANY OVERVIEW
  • TABLE 407 CREATIVE BIOARRAY: COMPANY OVERVIEW
  • TABLE 408 TISSUEARRAY.COM: COMPANY OVERVIEW
  • TABLE 409 IBIOCHIPS: COMPANY OVERVIEW
  • TABLE 410 CAPITALBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 411 PEPPERPRINT GMBH: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 BIOCHIPS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 BIOCHIPS MARKET: RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE)
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC INC.
  • FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: BIOCHIPS MARKET (2024)
  • FIGURE 10 DEMAND-SIDE MARKET ESTIMATION FOR BIOCHIPS
  • FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOCHIPS MARKET (2025-2030)
  • FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 13 TOP-DOWN APPROACH
  • FIGURE 14 BOTTOM-UP APPROACH
  • FIGURE 15 MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 16 BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 BIOCHIPS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 DNA CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 19 LAB-ON-A-CHIP MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 20 PROTEIN CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 21 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 22 BIOCHIPS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 23 GEOGRAPHIC SNAPSHOT OF BIOCHIPS MARKET
  • FIGURE 24 INCREASING INCIDENCE OF CHRONIC CONDITIONS TO FUEL MARKET
  • FIGURE 25 CONSUMABLES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024
  • FIGURE 26 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 27 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 28 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 29 BIOCHIPS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 30 BIOCHIPS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 31 BIOCHIPS MARKET: PATENT ANALYSIS, JANUARY 2014-OCTOBER 2025
  • FIGURE 32 TOP APPLICANTS FOR BIOCHIPS PATENTS, BY JURISDICTION, JANUARY 2014-OCTOBER 2025
  • FIGURE 33 AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP, BY KEY PLAYER, 2024
  • FIGURE 34 AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP, BY REGION, 2024
  • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS, BY PRODUCT
  • FIGURE 36 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 37 AI-USE CASES
  • FIGURE 38 BIOCHIPS MARKET: ECOSYSTEM MARKET MAP
  • FIGURE 39 BIOCHIPS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 40 BIOCHIPS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 41 REVENUE SHIFT AND NEW REVENUE POCKETS FOR BIOCHIPS MARKET
  • FIGURE 42 BIOCHIPS MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 43 NORTH AMERICA: BIOCHIPS MARKET SNAPSHOT
  • FIGURE 44 ASIA PACIFIC: BIOCHIPS MARKET SNAPSHOT
  • FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2020-2024
  • FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
  • FIGURE 47 RANKING OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
  • FIGURE 48 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 EV/EBITDA OF KEY VENDORS
  • FIGURE 51 BIOCHIPS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 52 R&D EXPENDITURE OF KEY PLAYERS IN BIOCHIPS MARKET, 2022-2024
  • FIGURE 53 BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 54 BIOCHIPS MARKET: COMPANY FOOTPRINT
  • FIGURE 55 BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 56 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 59 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
  • FIGURE 60 QIAGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 62 ABBOTT: COMPANY SNAPSHOT (2024)
  • FIGURE 63 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024)
  • FIGURE 64 10X GENOMICS: COMPANY SNAPSHOT (2024)
  • FIGURE 65 BIOMERIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 66 REVVITY: COMPANY SNAPSHOT (2024)
  • FIGURE 67 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024)